Chris Conn
Global Director, Diagnostics Strategy Amgen
Seminars
Thursday 5th February 2026
Panel Discussion: Accelerating the Use of MRD as a Surrogate Endpoint Across Indications
9:30 am
- Leveraging existing MRD evidence from hematology (e.g. multiple myeloma) to inform regulatory and policy pathways in new settings
- Driving alignment on assays, thresholds, endpoints, and timepoints to ensure cross-study comparability and reproducibility
- Building collaborative frameworks and secure data-sharing models to generate the robust evidence required by regulators and payers
Thursday 5th February 2026
Closing Remarks: Liquid Biopsy in Precision Medicine – From Proof-of-Concept to Routine Clinical Practice
4:00 pm
- Moving from niche to a routine clinical tool: advancements in liquid biopsy over the last 10 years
- Challenges and opportunities as we look to the next 10 years of liquid biopsy in precision medicine
- Future directions and emerging technologies to address unmet needs
Thursday 5th February 2026
Chair’s Opening Remarks
8:20 am
